Johnson & Johnson reports weaker-than-expected Q4 revenue but issues strong guidance for the full year. CFO Joseph Wolk discussed on CNBC.Johnson & Johnson reports weaker-than-expected Q4 revenue but issues strong guidance for the full year. CFO Joseph Wolk discussed on CNBC.
Johnson & Johnson (JNJ) stock is trading higher premarket after the company's Q4 results and an EPS outlook seen above estimates.Q4 adjusted EPS grew +10.3% Y/Y to $2.35, beating...Johnson & Johnson (JNJ) stock is trading higher premarket after the company's Q4 results and an EPS outlook seen above estimates.Q4 adjusted EPS grew +10.3% Y/Y to $2.35, beating...
Check out this infographic breakdown of the company’s fourth- quarter and annual performance.Check out this infographic breakdown of the company’s fourth-quarter and annual performance, with highlights from its Pharmaceutical, MedTech and Consumer Health businesses.
(Reuters) -Johnson & Johnson on Tuesday said it sees the impact from high inflation carrying into 2023 and expects China's major COVID-19 outbreak to dent sales at its medical devices unit in the first half of the year. J&J forecast 2023 sales of $96.9 billion to $97.9 billion, putting the midpoint of the range below Wall Street estimates, while fourth-quarter profit came in ahead of expectations due to cost management and strong demand for some prescription medicines despite lower-than-expected medical device sales. "Given all the macroeconomic uncertainty, geopolitical uncertainty, we thought this was the right approach at this point in time to come out with guidance in the ranges that we did," Chief Financial Officer Joseph Wolk said on a conference call.(Reuters) -Johnson & Johnson on Tuesday said it sees the impact from high inflation carrying into 2023 and expects China's major COVID-19 outbreak to dent sales at its medical devices unit in the first half of the year. J&J forecast 2023 sales of $96.9 billion to $97.9 billion, putting the midpoint of the range below Wall Street estimates, while fourth-quarter profit came in ahead of expectations due to cost management and strong demand for some prescription medicines despite lower-than-expected medical device sales. "Given all the macroeconomic uncertainty, geopolitical uncertainty, we thought this was the right approach at this point in time to come out with guidance in the ranges that we did," Chief Financial Officer Joseph Wolk said on a conference call.
Johnson & Johnson on Tuesday forecast annual profit above Wall Street estimates.Johnson & Johnson on Tuesday forecast annual profit above Wall Street estimates.
Johnson & Johnson (JNJ) is set to kick-off pharma earnings season with its Q4 earnings results on Tuesday, January 24th, before market open, amid a challenging macro...Johnson & Johnson (JNJ) is set to kick-off pharma earnings season with its Q4 earnings results on Tuesday, January 24th, before market open, amid a challenging macro...